AKTS
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopharmaceuticals for solid tumors, Aktis Oncology builds its medicines from tiny engineered proteins called miniproteins that slip deep into tumors and clear quickly from the body. Its lead candidate targets Nectin-4, found on bladder and other cancers, while a second program targets B7-H3 for prostate and lung cancers. The company has a discovery collaboration with Eli Lilly and is building its own manufacturing facility.
CUSIP: 01021M104HealthcareUS2 holders
Total Value
$9.97M
Total Shares
309.4K
Net Share Change
-20.1K
Activity
1 buying1 selling
Investor
Value
Shares
Weight
Change
